Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial ResultsGlobeNewsWire • 08/08/24
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific SessionsGlobeNewsWire • 06/24/24
Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of ShareholdersGlobeNewsWire • 06/17/24
Veru to Present at the American Diabetes Association's 84th Scientific SessionsGlobeNewsWire • 06/10/24
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology WeekGlobeNewsWire • 05/14/24
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical ProgramGlobeNewsWire • 05/08/24
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight LossGlobeNewsWire • 04/30/24
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11GlobeNewsWire • 04/25/24
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight LossGlobeNewsWire • 03/12/24
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-QGlobeNewsWire • 02/28/24
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight LossGlobeNewsWire • 02/20/24